Neovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy

Table 2

Baseline factors of patients with neovascular age-related macular degeneration aged ≥90 years enrolled in Aflibercept or Ranibizumab treatment, which remained in treatment for at least the follow-up after the loading dose phase.

	Aflibercept ()	Ranibizumab ()	value
Age, years, median (IQR)	91 (90 to 93)	91 (90 to 92)	0.400
Gender, n (%)			0.370
Female	35 (71)	45 (79)
Male	14 (29)	12 (21)
BCVA, ETDRS letters, mean (SD)	50 (14)	48 (18)	0.510
Average CRT, mean (SD)	433 (130)	445 (114)	0.660
Lesion type, n (%)^†			0.309
Predominantly classic	16 (35)	18 (34)
Predominantly occult	25 (54)	34 (64)
Retinal angiomatous proliferation	5 (11)	1 (2)

IQR: interquartile range; SD: standard deviation; BCVA: best-corrected visual acuity; CRT: central retinal thickness.^†No data on lesion type for three patients in the Aflibercept group and four patients in the Ranibizumab group due to allergies to the contrast agents, lack of cooperation, or inaccessible data. values were calculated using the Mann–Whitney U test for age, χ²-test for gender, independent samples t-test for BCVA and average CRT, and Fisher’s exact test for lesion type due to groups with <5.